Amgen Inc. stock faces pressure amid 2026 guidance scrutiny and sector headwinds

Amgen Inc. (ISIN: US0311621009) released its 2026 revenue forecast of $37-38.4 billion and non-GAAP EPS of $21.60-$23.00, positioning the biotech giant for steady growth despite recent market volatility. German-speaking investors eye the stock's dividend appeal and pipeline resilience.

Amgen Inc. stock came under pressure this week as investors digested the company's freshly released 2026 guidance, projecting revenue between $37.0 billion and $38.4 billion alongside non-GAAP earnings per share of $21.60 to $23.00. The outlook, while signaling continued expansion in a maturing biotech landscape, highlighted potential headwinds from patent cliffs and competitive pressures in key franchises like Repatha and Prolia. For DACH investors, the development underscores Amgen's role as a defensive biotech play with robust dividend yields, offering stability amid European market uncertainties and rising interest rate sensitivities in healthcare portfolios.

As of: 19.03.2026

By Dr. Elena Voss, Senior Biotech Equity Analyst – Tracking Amgen's pipeline evolution and dividend sustainability in the context of global pharma shifts.

Guidance Breakdown: Steady Growth Amid Execution Risks

Amgen's 2026 projections build on a foundation of blockbuster drugs driving mid-single-digit revenue growth. The forecast anticipates total sales expansion from current levels, fueled by volume gains in obesity treatments and rare disease therapies. Management emphasized operational efficiencies to support the EPS range, which implies margin expansion through cost controls.

Key to this outlook is the performance of Enbrel and Otezla, which face biosimilar erosion but benefit from expanded indications. Amgen's rare disease portfolio, including Kyprolis and Blincyto, provides high-margin offsets. Investors reacted cautiously, as the guidance fell slightly short of aggressive Wall Street expectations baked into recent valuations.

The numbers position Amgen for a compound annual growth rate aligning with sector medians. This conservative stance reflects prudent planning around U.S. pricing reforms and European reimbursement hurdles, directly relevant for DACH portfolios tracking transatlantic pharma flows.

Pipeline Catalysts: Obesity and Beyond

Amgen's pipeline remains a cornerstone, with MariTide, its experimental obesity drug, advancing through Phase 3 trials. Early data suggest competitive weight loss profiles against leaders like Eli Lilly's Zepbound, potentially unlocking a multi-billion market. Success here could accelerate revenue beyond 2026 guidance.

In oncology, tarlatamab for small cell lung cancer showed promising survival data, expanding Amgen's presence in solid tumors. Bone health franchise extensions for Evenity target postmenopausal osteoporosis, addressing demographic-driven demand in aging DACH populations. These catalysts counterbalance generic pressures on legacy products.

Biotech metrics like peak sales potential and approval probabilities drive trader interest. Amgen's diversification reduces single-asset risk, appealing to conservative investors seeking pipeline optionality without pure-play volatility.

Valuation Metrics: Trading at a Discount?

Amgen trades at a forward P/E of approximately 24.6x, below sector averages amid quality dividend appeal. Price-to-sales stands at 4.3x LTM revenue, reflecting mature growth profile versus high-flying biotech peers. Upside to analyst targets hovers around 18%, per consensus.

Dividend yield remains attractive at levels supporting income-focused strategies. Buyback capacity bolsters shareholder returns, with recent authorizations signaling confidence. For DACH investors, these metrics compare favorably to European pharma peers grappling with reimbursement caps.

Relative value shines in peer comparisons: Amgen's P/B of 23.5x premiums book but justifies intangible assets like patents. Market multiples suggest room for re-rating if guidance beats materialize.

DACH Investor Relevance: Dividend Anchor in Volatile Times

German-speaking investors allocate heavily to U.S. biotech for diversification, with Amgen fitting as a high-conviction holding. Its stable cash flows fund consistent dividends, hedging against DAX volatility and Swiss market rate risks. Exposure via ETFs like quality dividend funds amplifies accessibility.

Reimbursement dynamics in Germany and Austria favor Amgen's established labels, with Prolia and Repatha securing HTA approvals. Switzerland's premium pricing environment boosts effective yields. Portfolio managers cite Amgen's low-beta profile for risk-adjusted returns.

Tax-efficient structures like Irish-domiciled UCITS enhance appeal, minimizing withholding frictions. Amid EU pharma regulations, Amgen's U.S.-centric model insulates from local policy shifts.

Market Reaction and Trading Dynamics

The Amgen Inc. stock on Nasdaq declined around 2.94% to approximately 307.50 USD in recent sessions, reflecting broad sector rotation. Volume spiked on guidance release, with intraday lows testing support levels. S&P 500 context shows biotech lagging amid tech rallies.

Analyst updates post-earnings maintained buy ratings, citing undervalued growth. Short interest remains low, limiting downside catalysts. Options flow indicates hedging rather than outright bearishness.

Risks and Open Questions

Patent expirations loom for Enbrel by late decade, pressuring 20% of revenues. Obesity pipeline competition intensifies, with trial delays possible. Regulatory scrutiny on drug pricing escalates under potential U.S. policy shifts.

Macro risks include inflation impacting R&D costs and reimbursement in Europe. Execution on acquisitions like Horizon Therapeutics integration remains key. Geopolitical tensions could disrupt supply chains for biologics.

Volatility persists if Phase 3 readouts disappoint. Investors weigh these against Amgen's fortress balance sheet and 40+ year track record.

Amgen Inc. stock holds appeal as a quality compounder. DACH portfolios benefit from its resilience, but vigilance on catalysts is essential.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.